血浆中抗逆转录病毒药物测量的国际实验室间质量控制计划
International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.
作者信息
Aarnoutse Rob E, Verweij-van Wissen Corrien P W G M, van Ewijk-Beneken Kolmer Eleonora W J, Wuis Eveline W, Koopmans Peter P, Hekster Yechiel A, Burger David M
机构信息
Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2002 Mar;46(3):884-6. doi: 10.1128/AAC.46.3.884-886.2002.
Abstract
An international interlaboratory quality control program for measurement of antiretroviral drugs was initiated. The first round was confined to protease inhibitors and showed large variability in the performance of participating laboratories. The results demonstrate the need for and utility of an ongoing quality control program in this area of bioanalysis.
摘要
启动了一项用于抗逆转录病毒药物测量的国际实验室间质量控制计划。第一轮仅限于蛋白酶抑制剂，结果显示参与实验室的表现存在很大差异。这些结果证明了在生物分析这一领域持续开展质量控制计划的必要性和实用性。
相似文献
1
International interlaboratory quality control program for measurement of antiretroviral drugs in plasma.
Antimicrob Agents Chemother. 2002 Mar;46(3):884-6. doi: 10.1128/AAC.46.3.884-886.2002.
2
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.
Ther Drug Monit. 2011 Apr;33(2):239-43. doi: 10.1097/FTD.0b013e31820fa528.
3
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.
J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):287-91. doi: 10.1097/00126334-200303010-00007.
4
Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring.
Ther Drug Monit. 2006 Jun;28(3):367-74. doi: 10.1097/01.ftd.0000211817.58052.b8.
5
Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.
Antimicrob Agents Chemother. 2004 Mar;48(3):824-31. doi: 10.1128/AAC.48.3.824-831.2004.
6
Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum.
Ther Drug Monit. 2014 Dec;36(6):824-7. doi: 10.1097/FTD.0000000000000089.
7
Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection.
J Chromatogr B Biomed Sci Appl. 1999 Jan 22;721(2):239-47. doi: 10.1016/s0378-4347(98)00451-4.
8
Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
J Chromatogr. 1992 Dec 23;584(2):239-47. doi: 10.1016/0378-4347(92)80581-a.
9
Resistance to antiretroviral drugs.
Antivir Ther. 1998;3 Suppl 4:5-7.
10
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 15;877(11-12):1057-69. doi: 10.1016/j.jchromb.2009.02.057. Epub 2009 Feb 28.
引用本文的文献
1
Adding value to antiretroviral proficiency testing.
Bioanalysis. 2014 Oct;6(20):2721-32. doi: 10.4155/bio.14.139.
2
Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories.
Ther Drug Monit. 2013 Oct;35(5):631-42. doi: 10.1097/FTD.0b013e31828f5088.
3
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.
Can J Hosp Pharm. 2009 Nov;62(6):500-9. doi: 10.4212/cjhp.v62i6.849.
4
Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.
Clin Pharmacokinet. 2011 Mar;50(3):143-89. doi: 10.2165/11539260-000000000-00000.
5
Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.
Ther Drug Monit. 2010 Aug;32(4):458-66. doi: 10.1097/FTD.0b013e3181e4427a.
6
Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?
Ther Drug Monit. 2010 Jun;32(3):273-81. doi: 10.1097/FTD.0b013e3181dca14b.
7
Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.
Antimicrob Agents Chemother. 2009 Jun;53(6):2532-8. doi: 10.1128/AAC.01374-08. Epub 2009 Mar 2.
8
International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.
Antimicrob Agents Chemother. 2009 Jan;53(1):303-5. doi: 10.1128/AAC.00901-08. Epub 2008 Nov 17.
9
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
Drug Alcohol Depend. 2007 Dec 1;91(2-3):269-78. doi: 10.1016/j.drugalcdep.2007.06.007. Epub 2007 Jul 23.
10
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.
J Clin Invest. 2005 Jul;115(7):1828-38. doi: 10.1172/JCI22954.
本文引用的文献
1
High-performance liquid chromatography of HIV protease inhibitors in human biological matrices.
J Chromatogr B Biomed Sci Appl. 2001 Nov 25;764(1-2):363-84. doi: 10.1016/s0378-4347(01)00344-9.
2
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
Clin Infect Dis. 2000 Jun;30 Suppl 2:S151-9. doi: 10.1086/313852.
3
Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection.
Ther Drug Monit. 2000 Feb;22(1):122-6. doi: 10.1097/00007691-200002000-00026.
4
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
J Chromatogr B Biomed Sci Appl. 1999 Apr 30;727(1-2):139-49. doi: 10.1016/s0378-4347(99)00079-1.
5
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Clin Pharmacokinet. 1999 Apr;36(4):289-304. doi: 10.2165/00003088-199936040-00004.
6
Proficiency testing in laboratory medicine: uses and limitations.
Arch Pathol Lab Med. 1998 Jan;122(1):15-30.
7
Proficiency testing programs--promises, progress, and problems. A 40-year prospective.
Arch Pathol Lab Med. 1988 Apr;112(4):329-33.
Zotero 插件